Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Treating Inflammation in Cataract Surgery Patients

This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.

Inclusion Criteria:

• Male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation.

Exclusion Criteria:

• Patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to Day 0.
• Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to screening.
• Patients with any signs of intraocular inflammation in either eye at screening.
• Patients who have received any prior intravitreal injections in the study eye.